Bridging Interventional Development Gaps program
E93887
The Bridging Interventional Development Gaps program is a National Center for Advancing Translational Sciences initiative that provides resources and expertise to help advance promising therapeutic candidates through critical preclinical and early clinical development stages.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
NCATS program
→
drug development support program → therapeutic development initiative → |
| aimsTo |
advance promising therapeutic candidates
→
|
| collaboratesWith |
academic medical centers
→
industry partners → patient advocacy groups → |
| country |
United States
→
|
| emphasis |
first-in-human enabling studies
→
rare and orphan diseases → unmet medical needs → |
| field |
drug development
→
translational science → |
| focusesOn |
critical preclinical development stages
→
early clinical development stages → |
| fundingModel |
collaborative agreements
→
in-kind support → |
| goal |
bridge gaps between basic research and clinical application
→
de-risk therapeutic candidates for further development → |
| objective |
accelerate translation of discoveries into therapies
→
reduce time and risk in early drug development → |
| offers |
clinical protocol development assistance
→
formulation development → manufacturing support → pharmacokinetics studies → regulatory strategy support → toxicology studies → |
| operatedBy |
National Center for Advancing Translational Sciences
NERFINISHED
→
|
| parentOrganization |
National Institutes of Health
→
|
| partOf |
National Center for Advancing Translational Sciences
NERFINISHED
→
|
| provides |
drug development expertise
→
resources for therapeutic development → |
| selectionProcess |
competitive application review
→
|
| sponsor |
early clinical development projects
→
preclinical development projects → |
| supports |
biologics
→
gene therapies → small molecules → therapeutics for neglected diseases → therapeutics for rare diseases → |
| supportsStage |
IND-enabling studies
→
Phase I clinical trials → proof-of-concept clinical studies → |
| targetAudience |
academic investigators
→
nonprofit research organizations → small biotechnology companies → |
Referenced by (1)
| Subject (surface form when different) | Predicate |
|---|---|
|
National Center for Advancing Translational Sciences
→
|
operates |